Avalo Therapeutics, Inc. Share Price

Equities

AVTX

US05338F3064

Biotechnology & Medical Research

Delayed Nasdaq 15:24:05 17/07/2024 BST 5-day change 1st Jan Change
12.07 USD -3.46% Intraday chart for Avalo Therapeutics, Inc. -3.81% +32.61%
Sales 2024 * - Sales 2025 * - Capitalization 12.93M 994M
Net income 2024 * -147M -11.3B Net income 2025 * -36M -2.77B EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-0.44 x
P/E ratio 2025 *
-12.5 x
Employees 19
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.26%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.16%
1 week-3.81%
Current month-3.23%
1 month+5.21%
3 months-11.40%
6 months+200.18%
Current year+32.61%
More quotes
1 week
11.74
Extreme 11.7399
12.75
1 month
10.70
Extreme 10.7005
14.00
Current year
3.95
Extreme 3.9501
34.46
1 year
3.95
Extreme 3.9501
82.06
3 years
3.95
Extreme 3.9501
9 331.13
5 years
3.95
Extreme 3.9501
17 827.06
10 years
3.95
Extreme 3.9501
22 031.54
More quotes
Managers TitleAgeSince
Chief Executive Officer 70 31/01/20
Director of Finance/CFO 40 31/12/17
Chief Operating Officer - -
Members of the board TitleAgeSince
Director/Board Member 67 09/11/21
Director/Board Member 76 11/10/20
Chief Executive Officer 70 31/01/20
More insiders
Date Price Change Volume
17/07/24 12.07 -3.46% 679
16/07/24 12.5 -1.19% 4,480
15/07/24 12.65 +4.03% 14,307
12/07/24 12.16 +1.33% 2,443
11/07/24 12 -4.34% 54,381

Delayed Quote Nasdaq, July 17, 2024 at 03:24 pm

More quotes
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
12.5 USD
Average target price
35 USD
Spread / Average Target
+180.00%
Consensus